Home Cart Sign in  
Chemical Structure| 1817626-54-2 Chemical Structure| 1817626-54-2

Structure of Zimlovisertib
CAS No.: 1817626-54-2

Chemical Structure| 1817626-54-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Zimlovisertib (PF-06650833) is an effective, selective, and orally bioavailable inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) with an IC50 of 0.2 nM, and an IC50 of 2.4 nM in PBMC assays. Zimlovisertib has potential for research in rheumatoid arthritis, lupus, and lymphoma.

Synonyms: PF-06650833

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Zimlovisertib

CAS No. :1817626-54-2
Formula : C18H20FN3O4
M.W : 361.37
SMILES Code : O=C(C1=CC2=C(C(OC[C@H]([C@H](CC)[C@@H]3F)NC3=O)=NC=C2)C=C1OC)N
Synonyms :
PF-06650833
MDL No. :MFCD30343869
InChI Key :JKDGKIBAOAFRPJ-ZBINZKHDSA-N
Pubchem ID :118414016

Safety of Zimlovisertib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Zimlovisertib

TLR

Isoform Comparison

Biological Activity

Description
Zimlovisertib (PF-06650833) is a potent, selective, and orally bioavailable inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), showing IC50 values of 0.2 nM in cell assays and 2.4 nM in peripheral blood mononuclear cell (PBMC) assays. It is primarily aimed at treating conditions such as rheumatoid arthritis, lupus, and lymphomas[1].[2].

In Vitro:

Cell Line
Concentration Treated Time Description References
Human peripheral blood mononuclear cells (hPBMC) 500 nmol/L 20 hours To evaluate the effect of PF-06650833 on cytokine secretion after LPS stimulation. Results showed that PF-06650833 effectively reduced the secretion of inflammatory cytokines such as IL-1, IFN-γ, TNF-α, and IL-17. PMC9339262
T cells 20 μM 96 hours To evaluate the effect of PF-06650833 on T cell proliferation and IFN-γ production, results showed that PF-06650833 significantly suppressed IFN-γ production by T cells without affecting their proliferation. PMC6939524

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Λ-carrageenan-induced paw edema and DSS-induced ulcerative colitis Intravenous injection 23 mg/kg Every other day for a total of four injections To evaluate the accumulation and anti-inflammatory effects of VCAM1-targeted nanocarriers in inflamed tissues. Results demonstrated that VCAM1-targeted nanocarriers significantly reduced paw edema and colitis symptoms, decreased proinflammatory cytokine levels in affected tissues, and showed no apparent systemic toxicity. PMC10840923
Female Balb/c mice Inhaled lipopolysaccharide (LPS)-induced ARDS mouse model Oral 100 mg/kg Preventive administration: one dose 30 min before modeling and another dose 6h after modeling; Therapeutic administration: two doses at 4 h and 12 h after modeling. To evaluate the therapeutic effect of PF-06650833 in the ARDS model. Results showed that although PF-06650833 exhibited excellent IRAK4 inhibitory activity in vitro, it failed to significantly alleviate lung injury or reduce inflammatory cell infiltration in the in vivo model. PMC9339262
Mice Graft-versus-host disease model Intravenous injection 12.0 mg/kg Once daily for 20 days To evaluate the effect of PF-06650833 on graft-versus-host disease, results showed that PF-06650833 significantly ameliorated morbidity and mortality of GvHD. PMC6939524
HuNOG-EXL mice CD34+ hematopoietic stem cell-engrafted NOG-EXL mice Oral 100 mg/kg Single dose, 30 minutes prior to challenge Evaluate the inhibitory effect of PF-06650833 on AZ617-induced human TNFα, significantly reducing circulating human TNFα PMC10691501

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03308110 Healthy PHASE1 COMPLETED 2018-01-11 Pfizer Clinical Research Unit,... More >> Brussels, B-1070, Belgium Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.77mL

0.55mL

0.28mL

13.84mL

2.77mL

1.38mL

27.67mL

5.53mL

2.77mL

References

 

Historical Records

Categories